Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Biomea Fusion (Nasdaq: BMEA) announced that Mick Hitchcock, Ph.D., Interim CEO and board member, will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA) announced that Mick Hitchcock, Ph.D., Interim CEO and board member, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 from 5:15 PM to 5:55 PM PT. Management will also host one-on-one meetings during the conference running January 12–15, 2026.
A live audio webcast of the presentation will be available on the company's Investors & Media website, with a replay posted after the live event.
Details
News Market Reaction – BMEA
On Dec 17, the day this news came out, BMEA closed 1.46% below the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Conference start date
- January 12, 2026
- Start of 44th Annual J.P. Morgan Healthcare Conference
- Conference end date
- January 15, 2026
- End of 44th Annual J.P. Morgan Healthcare Conference
- Company presentation date
- January 14, 2026
- Scheduled Biomea Fusion presentation date
- Presentation time window
- 5:15 PM–5:55 PM PT
- Duration of Biomea Fusion presentation at the conference
Historical Context
-
KOL interview and WCIRDC presentation on menin and icovamenib.
-
COVALENT-111 results showing durable glycemic and C-peptide benefits.
-
Announcement of upcoming oral icovamenib presentation at WCIRDC.
-
Inducement stock option grant under 2023 Inducement Equity Plan.
-
Participation in Piper Sandler and Evercore healthcare investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.
A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.